1142382-25-9

Basic information

• Product Name: 5-broMo-2-Methyl-4-nitroaniline
• Synonyms: 5-broMo-2-Methyl-4-nitroaniline
• CAS NO: 1142382-25-9
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.04668
• Mol File: 1142382-25-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMo-2-Methyl-4-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-2-Methyl-4-nitroaniline(1142382-25-9)
• EPA Substance Registry System: 5-broMo-2-Methyl-4-nitroaniline(1142382-25-9)

Safety Data

• Hazardous Substances Data: 1142382-25-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-methyl-4-nitroaniline is an organic compound with the chemical formula C7H7BrN2O2. It is a derivative of aniline with a bromine atom in the 5-position, a methyl group in the 2-position, and a nitro group in the 4-position. This chemical is used in the synthesis of pharmaceuticals, dyes, and agrochemicals. It is also employed as a reagent in organic synthesis and as a building block in the production of functional materials. However, it is important to handle this compound with caution as it is toxic and may cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 39478-78-9 5-bromo-2-methylaniline 

Downstream Products

• 1351813-02-9 6-bromo-5-nitro-1H-indazole 

Relevant articles and documents

N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

COMPOUNDS

Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).